{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:31:21Z","timestamp":1793968281899,"version":"4.8.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jcyt.2026.102956","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:42:47Z","timestamp":1784130167000},"page":"102956","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative analysis of advanced therapy regulatory frameworks in Latin America: perspectives from the ISCT South and Central America Legal and Regulatory Affairs Committee"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9594-2387","authenticated-orcid":false,"given":"Carolina","family":"Sep\u00falveda M\u00e1rquez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9881-435X","authenticated-orcid":false,"given":"Dominga","family":"Berrios P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardita","family":"Hurtado de Mendoza Urz\u00faa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin Hernan","family":"Bonamino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1532-4967","authenticated-orcid":false,"given":"Lilia Carolina","family":"Le\u00f3n-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4324-4083","authenticated-orcid":false,"given":"Mar\u00eda de Jes\u00fas","family":"Medina Arellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"G\u00f3mez-De Le\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando E.","family":"Figueroa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2026.102956_bib0001","unstructured":"Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA). Terapias avan\u00e7adas [Portuguese]. Bras\u00edlia: ANVISA. Available from: https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/sangue\/terapias-avancadas\/terapias-avancadas-1"},{"key":"10.1016\/j.jcyt.2026.102956_bib0002","series-title":"Disp\u00f5e sobre os produtos de terapias avan\u00e7adas [Internet]","article-title":"Resolu\u00e7\u00e3o da Diretoria Colegiada RDC n\u00b0 505, de 27 de maio de 2021","year":"2021"},{"key":"10.1016\/j.jcyt.2026.102956_bib0003","series-title":"Disp\u00f5e sobre as boas pr\u00e1ticas em ensaios cl\u00ednicos com produtos de terapias avan\u00e7adas experimentais","article-title":"Resolu\u00e7\u00e3o da Diretoria Colegiada RDC n\u00b0 506, de 27 de maio de 2021","year":"2021"},{"key":"10.1016\/j.jcyt.2026.102956_bib0004","series-title":"Requisitos para medicamentos de terapias avanzadas [Spanish]","article-title":"Alimentos y Tecnolog\u00eda M\u00e9dica (ANMAT). Disposici\u00f3n N\u00b0 179\/2018","year":"2018"},{"key":"10.1016\/j.jcyt.2026.102956_bib0005","series-title":"Norma t\u00e9cnica N.\u00b0 257: Medicamentos de terapias avanzadas. Decreto Exento N.\u00b0 11 [Spanish]","article-title":"Subsecretar\u00eda de Salud P\u00fablica","year":"2026"},{"key":"10.1016\/j.jcyt.2026.102956_bib0006","series-title":"Terapias avanzadas: una mirada desde el contexto Colombia (16-11-2017) [Spanish]","year":"2017"},{"key":"10.1016\/j.jcyt.2026.102956_bib0007","series-title":"Decreto 2493 de 2004: Por el cual se reglamentan parcialmente los art\u00edculos 19 y 23 de la Ley 9 de 1979 y se dictan otras disposiciones sobre componentes anat\u00f3micos y bancos de tejidos [Spanish]","article-title":"Ministerio de la Protecci\u00f3n Social","year":"2004"},{"key":"10.1016\/j.jcyt.2026.102956_bib0008","series-title":"Equipos y Dispositivos M\u00e9dicos de la Rep\u00fablica de Cuba [Internet] [Spanish]","article-title":"Equipos y Dispositivos M\u00e9dicos (CECMED). CECMED \u2013 Autoridad Reguladora Nacional de Medicamentos","year":"2026"},{"key":"10.1016\/j.jcyt.2026.102956_bib0009","series-title":"Norma Oficial Mexicana NOM-257-SSA1-2014, en materia de medicamentos biotecnol\u00f3gicos","year":"2014"},{"key":"10.1016\/j.jcyt.2026.102956_bib0010","series-title":"\u00daltima reforma vigente","article-title":"Congreso de la Uni\u00f3n. Ley General de Salud [Internet]","year":"1984"},{"key":"10.1016\/j.jcyt.2026.102956_bib0011","series-title":"Annex 3: Points to consider in the development of regulatory frameworks for human cells, tissues and advanced therapy products [Internet]","article-title":"WHO Expert Committee on Biological Standardization: seventy-fifth report","year":"2023"},{"key":"10.1016\/j.jcyt.2026.102956_bib0012","series-title":"Cellular & gene therapy products [Internet]","year":"2026"},{"key":"10.1016\/j.jcyt.2026.102956_bib0013","first-page":"121","article-title":"Regulation (EC) No. 1394\/2007 of the European Parliament and of the Council of 13 November 2007 on Advanced Therapy Medicinal Products and amending Directive 2001\/83\/EC and Regulation (EC) No. 726\/2004","volume":"L324","year":"2007","journal-title":"Off J Eur Union"},{"key":"10.1016\/j.jcyt.2026.102956_bib0014","series-title":"PIC\/S Guide to Good Manufacturing Practice for Medicinal Products PE 009-17 [Internet]","article-title":"Annex 2A: Manufacture of Advanced Therapy Medicinal Products","year":"2022"},{"key":"10.1016\/j.jcyt.2026.102956_bib0015","series-title":"PIC\/S members \u2013 Brazil (ANVISA) [Internet]","year":"2026"},{"key":"10.1016\/j.jcyt.2026.102956_bib0016","series-title":"ICH Harmonised Tripartite Guideline Q8 (R2): Pharmaceutical Development","year":"2009"},{"key":"10.1016\/j.jcyt.2026.102956_bib0017","series-title":"ICH Harmonised Guideline Q9 (R1): Quality Risk Management","year":"2023"},{"key":"10.1016\/j.jcyt.2026.102956_bib0018","series-title":"ICH Harmonised Tripartite Guideline Q10: Pharmaceutical Quality System","year":"2008"},{"key":"10.1016\/j.jcyt.2026.102956_bib0019","series-title":"ICH Harmonised Tripartite Guideline E2E: Pharmacovigilance Planning","year":"2004"},{"key":"10.1016\/j.jcyt.2026.102956_bib0020","series-title":"Regulatory system strengthening in the Americas: Recognition of national regulatory authorities of regional reference [Internet]","year":"2021"},{"key":"10.1016\/j.jcyt.2026.102956_bib0021","series-title":"Marco regulatorio del sistema nacional de donaci\u00f3n y trasplante [Internet] [Spanish]","year":"2026"},{"key":"10.1016\/j.jcyt.2026.102956_bib0022","series-title":"Ley de Trasplante de \u00d3rganos, Tejidos y C\u00e9lulas [Internet]","article-title":"Congreso de la Naci\u00f3n Argentina. Ley N.\u00b0 27.447","year":"2018"},{"key":"10.1016\/j.jcyt.2026.102956_bib0023","series-title":"Organigrama institucional y funciones del INAME [Internet] [Spanish]","article-title":"Alimentos y Tecnolog\u00eda M\u00e9dica (ANMAT)","year":"2026"},{"key":"10.1016\/j.jcyt.2026.102956_bib0024","series-title":"Requisitos para el registro y autorizaci\u00f3n de medicamentos biosimilares [Spanish]","article-title":"Alimentos y Tecnolog\u00eda M\u00e9dica (ANMAT). Disposici\u00f3n N\u00b0 7729\/2011","year":"2011"},{"key":"10.1016\/j.jcyt.2026.102956_bib0025","series-title":"Requerimientos y criterios para el ejercicio de comparabilidad de especialidades medicinales biosimilares [Spanish]","article-title":"Alimentos y Tecnolog\u00eda M\u00e9dica (ANMAT). Disposici\u00f3n N\u00b0 1741\/2025","year":"2025"},{"key":"10.1016\/j.jcyt.2026.102956_bib0026","series-title":"Requisitos para el registro de medicamentos biol\u00f3gicos obtenidos por tecnolog\u00eda de ADN recombinante y anticuerpos monoclonales [Spanish]","article-title":"Alimentos y Tecnolog\u00eda M\u00e9dica (ANMAT). Disposici\u00f3n N\u00b0 3397\/2012","year":"2012"},{"key":"10.1016\/j.jcyt.2026.102956_bib0027","series-title":"Procedimiento para solicitudes de inscripci\u00f3n en el Registro de Especialidades Medicinales (REM) mediante sistema de gesti\u00f3n electr\u00f3nica [Spanish]","article-title":"Alimentos y Tecnolog\u00eda M\u00e9dica (ANMAT). Circular N\u00b0 11\/2019","year":"2019"},{"key":"10.1016\/j.jcyt.2026.102956_bib0028","series-title":"Autorizaci\u00f3n efectiva de comercializaci\u00f3n de productos biol\u00f3gicos, vacunas y radiof\u00e1rmacos [Spanish]","article-title":"Alimentos y Tecnolog\u00eda M\u00e9dica (ANMAT). Disposici\u00f3n N\u00b0 9709\/2019","year":"2019"},{"key":"10.1016\/j.jcyt.2026.102956_bib0029","series-title":"Gu\u00eda para investigaciones con seres humanos y consideraciones aplicables a terapias celulares y g\u00e9nicas [Spanish]","article-title":"Ministerio de Salud. Resoluci\u00f3n N\u00b0 1480\/2011","year":"2011"},{"key":"10.1016\/j.jcyt.2026.102956_bib0030","series-title":"Decreto N\u00b0 150\/1992 reglamentario de la Ley N\u00b0 16.463 de medicamentos [Spanish]","article-title":"Poder Ejecutivo Nacional","year":"1992"},{"key":"10.1016\/j.jcyt.2026.102956_bib0031","series-title":"Alimentos y Tecnolog\u00eda M\u00e9dica (ANMAT). Certificado de autorizaci\u00f3n N\u00b0 59.372 \u2013 Zolgensma\u00ae [Spanish]","year":"2026"},{"key":"10.1016\/j.jcyt.2026.102956_bib0032","series-title":"Instru\u00e7\u00e3o Normativa n\u00b0 270\/2023 [Internet] [Portuguese]","year":"2023"},{"key":"10.1016\/j.jcyt.2026.102956_bib0033","series-title":"Organization chart [Internet]. [Portuguese]","year":"2026"},{"key":"10.1016\/j.jcyt.2026.102956_bib0034","series-title":"Comiss\u00e3o Nacional de \u00c9tica em Pesquisa (CONEP). Caderno 7: Sistema CEP\/CONEP e a regulamenta\u00e7\u00e3o da pesquisa envolvendo seres humanos [Internet] [Portuguese]","article-title":"Conselho Nacional de Sa\u00fade","year":"2026"},{"key":"10.1016\/j.jcyt.2026.102956_bib0035","series-title":"Documentos e registros de ensaios cl\u00ednicos autorizados para terapias avan\u00e7adas [Internet]","year":"2026"},{"key":"10.1016\/j.jcyt.2026.102956_bib0036","series-title":"Decreto Supremo N\u00b0 3\/2010: Aprueba Reglamento del Sistema Nacional de Control de Productos Farmac\u00e9uticos de Uso Humano [Internet] [Spanish]","year":"2011"},{"key":"10.1016\/j.jcyt.2026.102956_bib0037","series-title":"DFL 725\/1968 [Internet] [Spanish]","year":"1968"},{"key":"10.1016\/j.jcyt.2026.102956_bib0038","series-title":"Ley N\u00b0 20.850: Crea un sistema de protecci\u00f3n financiera para diagn\u00f3sticos y tratamientos de alto costo [Internet] [Spanish]","year":"2015"},{"key":"10.1016\/j.jcyt.2026.102956_bib0039","series-title":"Ley N\u00b0 20.120: Regula la investigaci\u00f3n cient\u00edfica en el ser humano, su genoma y proh\u00edbe la clonaci\u00f3n humana [Internet] [Spanish]","year":"2006"},{"key":"10.1016\/j.jcyt.2026.102956_bib0040","series-title":"Ley N\u00b0 19.451: Establece normas sobre trasplante y donaci\u00f3n de \u00f3rganos [Internet] [Spanish]","year":"1996"},{"key":"10.1016\/j.jcyt.2026.102956_bib0041","series-title":"Decreto Exento N\u00b0 32: Aprueba Norma General T\u00e9cnica N\u00b0 246 para tejido corneal [Spanish]","year":"2025"},{"key":"10.1016\/j.jcyt.2026.102956_bib0042","series-title":"Norma T\u00e9cnica N\u00b0 200: Para bancos de tejidos humanos [Internet] [Spanish]","year":"2018"},{"key":"10.1016\/j.jcyt.2026.102956_bib0043","series-title":"Norma T\u00e9cnica N\u00b0 173: Buenas pr\u00e1cticas de investigaci\u00f3n [Internet] [Spanish]","year":"2004"},{"key":"10.1016\/j.jcyt.2026.102956_bib0044","series-title":"Resoluci\u00f3n Exenta N\u00b0 0139: Gu\u00eda para instalaci\u00f3n y funcionamiento de bioterio [Spanish]","year":"2024"},{"key":"10.1016\/j.jcyt.2026.102956_bib0045","series-title":"Norma T\u00e9cnica N\u00b0 139: Buenas pr\u00e1cticas de laboratorio [Internet] [Spanish]","year":"2026"},{"key":"10.1016\/j.jcyt.2026.102956_bib0046","series-title":"Resoluci\u00f3n Exenta N\u00b0 273: Gu\u00eda t\u00e9cnica para estudios cl\u00ednicos con productos biol\u00f3gicos [Internet] [Spanish]","year":"2022"},{"key":"10.1016\/j.jcyt.2026.102956_bib0047","series-title":"Norma T\u00e9cnica N\u00b0 127: Buenas pr\u00e1cticas de manufactura para la industria farmac\u00e9utica [Internet] [Spanish]","year":"2012"},{"key":"10.1016\/j.jcyt.2026.102956_bib0048","series-title":"Decreto Exento N\u00b0 28\/2012 que aprueba Informe 33 de la OMS [Internet] [Spanish]","year":"2012"},{"key":"10.1016\/j.jcyt.2026.102956_bib0049","series-title":"Organigrama [Internet] [Spanish]","year":"2026"},{"key":"10.1016\/j.jcyt.2026.102956_bib0050","series-title":"Resoluci\u00f3n Exenta N\u00b0 E965\/25 que crea la Comisi\u00f3n para la Evaluaci\u00f3n de Terapias Avanzadas [Spanish]","year":"2025"},{"key":"10.1016\/j.jcyt.2026.102956_bib0051","series-title":"GICONA: Gestor de informaci\u00f3n de control y autorizaciones [Internet] [Spanish]","year":"2024"},{"key":"10.1016\/j.jcyt.2026.102956_bib0052","series-title":"Plataforma de estudios cl\u00ednicos ISP [Internet] [Spanish]","year":"2026"},{"key":"10.1016\/j.jcyt.2026.102956_bib0053","series-title":"Perspectiva de terapias avanzadas en el marco normativo (DDMOT 22-11-2016) [Internet] [Spanish]","year":"2016"},{"key":"10.1016\/j.jcyt.2026.102956_bib0054","series-title":"Proyecto de Decreto 1893 de 1994: Reglamentaci\u00f3n sobre medicamentos biotecnol\u00f3gicos [Internet] [Spanish]","article-title":"Ministerio de Salud","year":"1994"},{"key":"10.1016\/j.jcyt.2026.102956_bib0055","series-title":"Qui\u00e9nes somos \/Estructura organizacional [Internet] [Spanish]","article-title":"Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA)","year":"2026"},{"key":"10.1016\/j.jcyt.2026.102956_bib0056","series-title":"Componentes anat\u00f3micos \u2013 Dispositivos m\u00e9dicos [Internet] [Spanish]","article-title":"Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA)","year":"2026"},{"key":"10.1016\/j.jcyt.2026.102956_bib0057","unstructured":"Colombia. Ministerio de Salud y Protecci\u00f3n Social; Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA). Resoluci\u00f3n No. 2025001257 por la cual se concede un registro sanitario [Internet] [Spanish]. 2025 Jan 15 [cited 2026 Feb 15]. Available from: https:\/\/webservice.invima.gov.co\/registros\/pdf\/16688725_2025001257.pdf"},{"key":"10.1016\/j.jcyt.2026.102956_bib0058","series-title":"Resoluci\u00f3n 5108 de 2005: Por la cual se establecen los requisitos para la apertura y funcionamiento de los bancos de tejidos y m\u00e9dula \u00f3sea [Internet] [Spanish]","article-title":"Ministerio de la Protecci\u00f3n Social","year":"2005"},{"key":"10.1016\/j.jcyt.2026.102956_bib0059","series-title":"Decreto 2493 de 2004, por el cual se reglamentan parcialmente las Leyes 9 de 1979 y 73 de 1988 en relaci\u00f3n con los componentes anat\u00f3micos [Internet]","article-title":"Ministerio de la Protecci\u00f3n Social","year":"2004"},{"key":"10.1016\/j.jcyt.2026.102956_bib0060","series-title":"Resoluci\u00f3n No. 2024057527. Registro sanitario del medicamento Zolgensma\u00ae (onasemnogene abeparvovec) [Internet] [Spanish]","year":"2024"},{"key":"10.1016\/j.jcyt.2026.102956_bib0061","unstructured":"Valencia R\u00edos BF. \u00bfPor qu\u00e9 el medicamento que necesita Gael, un beb\u00e9 colombiano, es el m\u00e1s caro del mundo? El Colombiano [Internet] [Spanish]. 2025 May 28 [cited 2026 Feb 15]. Available from: https:\/\/www.elcolombiano.com\/colombia\/gael-bebe-colombiano-zolgensma-medicamento-mas-caro-del-mundo-LE27543383"},{"key":"10.1016\/j.jcyt.2026.102956_bib0062","series-title":"Regulaci\u00f3n sobre buenas pr\u00e1cticas de fabricaci\u00f3n de productos farmac\u00e9uticos en investigaci\u00f3n [Internet] [Spanish]","year":"2026"},{"key":"10.1016\/j.jcyt.2026.102956_bib0063","series-title":"Life sciences regulation in Mexico: Overview [Internet]","year":"2026"},{"key":"10.1016\/j.jcyt.2026.102956_bib0064","series-title":"Decreto por el que se reforman, adicionan y derogan diversas disposiciones de la Ley General de Salud","year":"2026"},{"key":"10.1016\/j.jcyt.2026.102956_bib0065","series-title":"Terapias con c\u00e9lulas madre para la cura de la enfermedad asociada a COVID-19 [Internet] [Spanish]","year":"2026"},{"key":"10.1016\/j.jcyt.2026.102956_bib0066","series-title":"Proyecto de Norma Oficial Mexicana PROY-NOM-260-SSA1-2017, para la disposici\u00f3n de c\u00e9lulas troncales y progenitoras con fines terap\u00e9uticos y de investigaci\u00f3n","year":"2017"},{"key":"10.1016\/j.jcyt.2026.102956_bib0067","series-title":"Norma Oficial Mexicana NOM-059-SSA1-2015, Buenas pr\u00e1cticas de fabricaci\u00f3n de medicamentos [Internet] [Spanish]","year":"2015"},{"key":"10.1016\/j.jcyt.2026.102956_bib0068","series-title":"Norma Oficial Mexicana NOM-073-SSA1-2015, Estabilidad de f\u00e1rmacos y medicamentos [Internet] [Spanish]","year":"2015"},{"key":"10.1016\/j.jcyt.2026.102956_bib0069","series-title":"Norma Oficial Mexicana NOM-220-SSA1-2016, Instalaci\u00f3n y operaci\u00f3n de la farmacovigilancia [Internet] [Spanish]","year":"2016"},{"key":"10.1016\/j.jcyt.2026.102956_bib0070","series-title":"Certificaci\u00f3n de buenas pr\u00e1cticas de fabricaci\u00f3n [Internet] [Spanish]","year":"2026"},{"key":"10.1016\/j.jcyt.2026.102956_bib0071","series-title":"Farmacovigilancia [Internet] [Spanish]","year":"2026"},{"key":"10.1016\/j.jcyt.2026.102956_bib0072","unstructured":"P\u00e9rez-Llorca. Legal Briefing: Amendment to the General Health Law. Decree published on January 15, 2026. [Spanish]. Madrid: P\u00e9rez-Llorca; 2026 [citado 2 mar 2026]. Disponible en: https:\/\/www.perezllorca.com\/wp-content\/uploads\/2026\/01\/Legal-Briefing-Amendment-to-the-General-Health-Law-Decree-published-on-January-15-2026.pdf"},{"key":"10.1016\/j.jcyt.2026.102956_bib0073","series-title":"Disp\u00f5e sobre as Boas Pr\u00e1ticas em C\u00e9lulas Humanas para Uso Terap\u00eautico e pesquisa cl\u00ednica e d\u00e1 outras provid\u00eancias [Internet]","article-title":"Resolu\u00e7\u00e3o da Diretoria Colegiada \u2013 RDC n\u00b0 836, de 14 de dezembro de 2023","year":"2023"},{"key":"10.1016\/j.jcyt.2026.102956_bib0074","article-title":"Regulation (EU) 2024\/1938 of the European Parliament and of the Council of 13 June 2024 on standards of quality and safety for substances of human origin intended for human application and repealing Directives 2002\/98\/EC and 2004\/23\/EC","year":"2024","journal-title":"Off J Eur Union"},{"key":"10.1016\/j.jcyt.2026.102956_bib0075","series-title":"Medical products of human origin (MPHO) [Internet]","year":"2026"},{"key":"10.1016\/j.jcyt.2026.102956_bib0076","series-title":"ICH Harmonised Tripartite Guideline Q5E: Comparability of Biotechnological\/Biological Products Subject to Changes in Their Manufacturing Process","year":"2004"},{"key":"10.1016\/j.jcyt.2026.102956_bib0077","series-title":"ICH Q6B: Specifications: Test Procedures and Acceptance Criteria for Biotechnological\/Biological Products","year":"1999"},{"key":"10.1016\/j.jcyt.2026.102956_bib0078","series-title":"ICH Q5A (R2): Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin [Internet]","year":"2023"},{"key":"10.1016\/j.jcyt.2026.102956_bib0079","series-title":"ICH S12: Nonclinical Biodistribution Considerations for Gene Therapy Products","year":"2023"},{"key":"10.1016\/j.jcyt.2026.102956_bib0080","series-title":"Fortalecimiento de los sistemas regulatorios nacionales de medicamentos y otras tecnolog\u00edas sanitarias en las Am\u00e9ricas [Internet] [Spanish]","year":"2021"},{"key":"10.1016\/j.jcyt.2026.102956_bib0081","series-title":"COFEPRIS mantiene reconocimiento como Autoridad Reguladora Nacional de Referencia Regional (ANRr) [Internet] [Spanish]","article-title":"Organizaci\u00f3n Mundial de la Salud","year":"2026"},{"key":"10.1016\/j.jcyt.2026.102956_bib0082","series-title":"Nota informativa sobre terapias celulares sin evidencia cient\u00edfica suficiente [Internet] [Spanish]","year":"2025"},{"key":"10.1016\/j.jcyt.2026.102956_bib0083","series-title":"Fiocruz advances with a national mRNA platform for vaccines and therapies [Internet]","year":"2025"},{"key":"10.1016\/j.jcyt.2026.102956_bib0084","series-title":"Empresarial de las Industrias Biotecnol\u00f3gica y Farmac\u00e9utica de Cuba [Internet] [Spanish]","year":"2026"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926009175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926009175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:22:48Z","timestamp":1793967768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324926009175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":84,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S1465324926009175"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102956","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative analysis of advanced therapy regulatory frameworks in Latin America: perspectives from the ISCT South and Central America Legal and Regulatory Affairs Committee","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102956","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Cell & Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102956"}}